CD3G

ROCKVILLE, Md. and SUZHOU, China, March 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024. The AACR meeting will take place April 5-10, 2024, in San Diego, California. Late-Breaking Research: Experimental and Molecular Therapeutics 1 Topic: IBI3001: a potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors Abstract Number: LB055 Presentation Form: Poster Presentation Time ：Sunday Apr 7, 2024 1:30 PM - 5:00 PM Location: Poster Section 53 Presenting Author: Dr. Kaijie He Topic: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors Abstract Number: LB056 Presentation Form: Poster Presentation Time ：Sunday Apr 7, 2024 1:30 PM - 5:00 PM Location: Poster Section 53 Presenting Author: Dr. Kaijie He Topic: Discovery and preclinical characterization of IBI343, a site-specifically conjugated anti-Claudin18.2 ADC for treating solid tumors Abstract Number: LB057 Presentation Form: Poster Presentation Time ：Sunday Apr 7, 2024 1:30 PM - 5:00 PM Location: Poster Section 53 Presenting Author: Dr. Kaijie He Poster Session: Immunology - Single Target and Bispecific Antibodies Topic: A novel TROP2-targeted immune stimulating antibody conjugate (ISAC) with potent anti-tumoral activity and acceptable safety Abstract Number: 2718 Presentation Form: Poster Presentation Time: Monday Apr 8, 2024 1:30 PM - 5:00 PM Location: Poster Section 6 Poster Board Number: 9 Presenting Author: Dr. Huizhong Xiong Poster Session: Immunology - Immune Modulation Employing Agonist or Co-Stimulatory Approaches Topic: Tumor targeted-CD28 bispecific antibody with optimized potency, robust anti-tumoral activity and stringent CD3-dependence Abstract Number: 5295 Presentation Form: Poster Presentation Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM Location: Poster Section 3 Poster Board Number: 4 Presenting Author: Dr. Huizhong Xiong Dr. Kaijie He, Vice President of Innovent, stated: "We aim to tackle drug resistance and enhance treatment outcomes in immunotherapy by developing next-generation bispecific antibodies, multi-specific antibodies and ADCs candidates. To select targets that can address broad-spectrum of tumor types is one of our main research direction. We are pleased to present preclinical data of innovative molecules at the AACR and accepted as Late-breaking Researches. We hope to benefit more patients with continuous advances in life science and technology. " About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable illnesses. Its pioneering therapies to treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 20 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Note: TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States. TYVYT® (sintilimab injection, Innovent) BYVASDA® (bevacizumab biosimilar injection, Innovent) HALPRYZA® (rituximab biosimilar injection, Innovent) SULINNO® (adalimumab biosimilar injection, Innovent) Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan. CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Disclaimer: Innovent does not recommend any off-label usage. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for this modality by generating molecules with the potential for improved efficacy and safety profiles for solid tumors and challenging targets such as peptide-MHCs. AbCellera will present four posters at AACR that demonstrate how it is leveraging its platform to develop T-cell engagers with potent tumor-cell killing and low cytokine release for multiple cancer targets. Using data integrated from across these programs, AbCellera will present new insights into T-cell engager function. In addition, AbCellera will present data on novel CD28-binding antibodies that can be used to optimize T-cell engagers, particularly for solid tumors that are difficult to treat using current immunotherapies. Details on AbCellera’s poster presentations at AACR are as follows: Title: Functional and specific T-cell engagers against a peptide-MHC tumor target Abstract Number: 2373 Session: Antibodies 1 Date and Time: Monday, April 8, 2024, 9:00 a.m. to 12:30 p.m. PT Location: Section 38, Board 19 Title: Diverse CD28-binding IgG and heavy chain-only antibodies for T-cell engager development Abstract Number: 1859 Session: Antibody-Based Technologies and New Inhibitors Date and Time: Monday, April 8, 2024, 9:00 a.m. to 12:30 p.m. PT Location: Section 22, Board 3 Title: Target-dependent considerations for the design of bispecific T-cell engagers Abstract Number: 1868 Session: Antibody-Based Technologies and New Inhibitors Date and Time: Monday, April 8, 2024, 9:00 a.m. to 12:30 p.m. PT Location: Section 22, Board 12 Title: Development of PSMA x CD3 T-cell engagers using an integrated, functional approach Abstract Number: 6359 Session: Antibodies 2 Date and Time: Tuesday, April 9, 2024, 1:30 p.m. to 5:00 p.m. PT Location: Section 41, Board 20 About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers are bispecific antibodies that guide the immune system to find and eliminate cancer cells by binding both cancer-killing T cells and tumor targets at the same time. Developing effective T-cell engagers requires two parental antibodies—a CD3-binding arm that fine-tunes T-cell activation and a tumor-binding arm with high specificity for cancer cells. The small number of available CD3-binding antibodies that can effectively fine-tune T-cell responses has been a barrier to T-cell engager development. To address this barrier, AbCellera developed a complete T-cell engager platform that includes fully human, developable CD3-binding antibodies with unique binding and functional properties. By combining these antibodies with OrthoMab™, its clinically validated multispecific engineering platform, and its antibody discovery and development engine, AbCellera’s T-cell engager platform is designed to bring new cancer medicines to the clinic faster. About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit . AbCellera Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. View source version on businesswire.com: Contacts Inquiries Media: Kathleen Reid; media@abcellera.com, +1(604)724-1242 Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116 Source: AbCellera Biologics Inc. View this news release online at:

The BLA for Regeneron’s linvoseltamab is based on data from the Phase I/II LINKER-MM1 clinical trial. Credit: lev radin / Shutterstock.com. The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals ’ biologics licence application (BLA) for linvoseltamab to treat multiple myeloma (MM), for priority review. An investigational bispecific antibody, linvoseltamab is aimed at adults with relapsed/refractory (r/r) MM who have undergone treatment with a minimum of three previous therapies. A decision on the regulatory approval from the FDA is anticipated by 22 August 2024. Linvoseltamab’s mechanism involves connecting the B-cell maturation antigen in MM cells to CD3-expressing T-cells, thereby activating the T-cells and promoting the destruction of cancer cells. The BLA for linvoseltamab is based on data from a current Phase I/II clinical trial known as LINKER-MM1. This open-label, multicentre trial enrolled 282 subjects. See Also: Sarilumab by Regeneron Pharmaceuticals for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval PepGen earns FDA fast track designation for myotonic dystrophy type 1 candidate The completed Phase I dose-escalation segment of the trial evaluated the tolerability, safety and dose-limiting toxicities linked to linvoseltamab at nine dose levels and on varying administration schedules. The ongoing Phase II dose-expansion stage will analyse the anti-tumour efficacy and safety of the therapy. The clinical development programme for linvoseltamab includes the LINKER-MM3 Phase III confirmatory trial for R/R MM patients, which is currently recruiting participants. Plans are in place for further trials targeting earlier stages of the disease and different lines of therapy, such as a Phase I/II trial for first-line therapy, a Phase II trial for high-risk smouldering MM, and a Phase II trial for monoclonal gammopathy of undetermined significance. A Phase I trial is also planned to explore the combination of linvoseltamab with a Regeneron CD38xCD28 costimulatory bispecific in MM treatment.